These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19075865)

  • 1. ErbB antagonists patenting: "playing chess with cancer".
    Aifa S; Rebai A
    Recent Pat Biotechnol; 2008; 2(3):181-7. PubMed ID: 19075865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
    Hamid O
    J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
    Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the EGFR pathway for cancer therapy.
    Johnston JB; Navaratnam S; Pitz MW; Maniate JM; Wiechec E; Baust H; Gingerich J; Skliris GP; Murphy LC; Los M
    Curr Med Chem; 2006; 13(29):3483-92. PubMed ID: 17168718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecules with EGFR-TK inhibitor activity.
    Albanell J; Gascón P
    Curr Drug Targets; 2005 May; 6(3):259-74. PubMed ID: 15857287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
    Zhu Z
    Acta Pharmacol Sin; 2007 Sep; 28(9):1476-93. PubMed ID: 17723181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
    Normanno N; Bianco C; De Luca A; Maiello MR; Salomon DS
    Endocr Relat Cancer; 2003 Mar; 10(1):1-21. PubMed ID: 12653668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR targeting of solid tumors.
    Rocha-Lima CM; Soares HP; Raez LE; Singal R
    Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.